دورية أكاديمية
Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study.
| العنوان: | Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study. |
|---|---|
| المؤلفون: | Jeong SH; Department of Hematology-Oncology, Ajou University Hospital, Suwon, Korea., Kim SJ; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Yoon DH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea., Park Y; Department of Internal Medicine, Korea University Anam Hospital, Seoul, Korea., Kang HJ; Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea., Koh Y; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea., Lee GW; Divison of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Korea., Lee WS; Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, Korea., Yang DH; Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, Korea., Do YR; Department of Medicine, Dongsan Medical Center, Daegu, Korea., Kim MK; Department of Medicine, Yeungnam University College of Medicine, Daegu, Korea., Yoo KH; Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea., Choi YS; Department of Hematology-Oncology, Ajou University Hospital, Suwon, Korea., Yun HJ; Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea., Yi JH; Department of Internal Medicine, Chung-Ang University Hospital, Seoul, Korea., Jo JC; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea., Eom HS; Hematology-Oncology Clinic, National Cancer Center, Goyang, Korea., Kwak JY; Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, Korea., Shin HJ; Department of Internal Medicine, Pusan National University Hospital, Busan, Korea., Park BB; Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea., Hyun SY; Department of Internal medicine, Yonsei University Wonju College of medicine, Wonju, Korea., Yi SY; Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Korea., Kwon JH; Department of Internal Medicine, Chungbuk National University Hospital, Chungju, Korea., Oh SY; Department of Internal Medicine, Dong-A University Medical Center, Busan, Korea., Kim HJ; Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea., Sohn BS; Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul, Korea., Won JH; Department of Hematology-Oncology, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine, Seoul, Korea., Kim SH; Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea., Lee HS; Department of Internal Medicine, Kosin University Gospel Hospital, Busan, Korea., Suh C; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea., Kim WS; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. |
| المصدر: | Cancer research and treatment [Cancer Res Treat] 2022 Oct; Vol. 54 (4), pp. 1268-1277. Date of Electronic Publication: 2021 Dec 30. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: The Association Country of Publication: Korea (South) NLM ID: 101155137 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2005-9256 (Electronic) Linking ISSN: 15982998 NLM ISO Abbreviation: Cancer Res Treat Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Seoul, Korea : The Association, |
| مواضيع طبية MeSH: | Febrile Neutropenia*/chemically induced , Febrile Neutropenia*/prevention & control , Lymphoma, Large B-Cell, Diffuse*/pathology, Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cyclophosphamide/adverse effects ; Doxorubicin/adverse effects ; Filgrastim ; Granulocyte Colony-Stimulating Factor/therapeutic use ; Humans ; Polyethylene Glycols ; Prednisolone/therapeutic use ; Prednisone/adverse effects ; Prospective Studies ; Rituximab/therapeutic use ; Vincristine/therapeutic use |
| مستخلص: | Purpose: Febrile neutropenia (FN) can cause suboptimal treatment and treatment-related mortality (TRM) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP). Materials and Methods: We conducted a prospective cohort study to evaluate the effectiveness of pegfilgrastim prophylaxis in DLBCL patients receiving R-CHOP, and we compared them with the PROCESS cohort (n=485). Results: Since January 2015, 986 patients with DLBCL were enrolled. Pegfilgrastim was administered at least once in 930 patients (94.3%), covering 90.3% of all cycles. FN developed in 137 patients (13.9%) in this cohort (23.7% in the PROCESS cohort, p<0.001), and 4.2% of all cycles (10.2% in the PROCESS cohort, p<0.001). Dose delay was less common (≥3 days: 18.1% vs. 23.7%, p=0.015; ≥5 days: 12.0% vs. 18.3%, p=0.023) in this cohort than in the PROCESS cohort. The incidence of TRM (3.2% vs. 5.6%, p=0.047) and infection-related death (1.8% vs. 4.5%, p=0.004) was lower in this cohort than in the PROCESS cohort. The 4-year overall survival (OS) and progression-free survival (PFS) rates of the two cohorts were not different (OS: 73.0% vs. 71.9%, p=0.545; PFS: 69.5% vs. 68.8%, p=0.616). However, in patients aged ≥75 years, the 4-year OS and PFS rates were higher in this cohort than in the PROCESS cohort (OS: 49.6% vs. 33.7%, p=0.032; PFS: 44.2% vs. 30.3% p=0.047). Conclusion: Pegfilgrastim prophylaxis is effective in the prevention of FN and infection-related death in DLBCL patients receiving R-CHOP, and it also improves OS in patients aged ≥75 years. |
| References: | Support Care Cancer. 2020 Feb;28(2):571-579. (PMID: 31093770) Leuk Res. 2012 May;36(5):548-53. (PMID: 22385870) J Med Econ. 2013;16(1):160-8. (PMID: 23016568) Lancet Oncol. 2011 May;12(5):460-8. (PMID: 21482186) Leuk Lymphoma. 2020 Oct;61(10):2435-2441. (PMID: 32529865) Leuk Lymphoma. 2000 Apr;37(3-4):351-60. (PMID: 10752986) N Engl J Med. 2002 Jan 24;346(4):235-42. (PMID: 11807147) Support Care Cancer. 2012 Mar;20(3):647-52. (PMID: 22101611) Blood Adv. 2021 May 11;5(9):2426-2437. (PMID: 33961018) Leuk Lymphoma. 2003 Dec;44(12):2069-76. (PMID: 14959849) Pharmacoeconomics. 2017 Apr;35(4):425-438. (PMID: 27928760) Int J Hematol. 2018 Apr;107(4):395-404. (PMID: 29357080) J Natl Compr Canc Netw. 2017 Dec;15(12):1520-1541. (PMID: 29223990) J Korean Med Sci. 2014 Nov;29(11):1493-500. (PMID: 25408580) Cancer Med. 2019 Mar;8(3):1103-1109. (PMID: 30740919) Eur J Cancer. 2011 Jan;47(1):8-32. (PMID: 21095116) J Clin Oncol. 2014 Sep 20;32(27):3059-68. (PMID: 25113753) J Natl Compr Canc Netw. 2008 Feb;6(2):109-18. (PMID: 18319047) Hematol Oncol. 2011 Dec;29(4):177-84. (PMID: 21246591) Int J Hematol. 2021 Jun;113(6):823-831. (PMID: 33738702) Lancet Oncol. 2011 Oct;12(11):1013-22. (PMID: 21940214) BMC Cancer. 2013 Jan 08;13:11. (PMID: 23298389) Expert Rev Pharmacoecon Outcomes Res. 2017 Feb;17(1):39-52. (PMID: 28064553) Oncotarget. 2016 Nov 1;7(44):72033-72043. (PMID: 27713132) Crit Rev Oncol Hematol. 2014 Jun;90(3):190-9. (PMID: 24434034) Ann Oncol. 2002 Jun;13(6):903-9. (PMID: 12123336) J Med Econ. 2014 Jan;17(1):32-42. (PMID: 24028444) BMC Cancer. 2019 Aug 9;19(1):792. (PMID: 31399079) J Clin Oncol. 2002 Feb 1;20(3):727-31. (PMID: 11821454) Oncotarget. 2017 Sep 18;8(54):92171-92182. (PMID: 29190906) |
| معلومات مُعتمدة: | Consortium for Improving Survival of Lymphoma |
| فهرسة مساهمة: | Keywords: Diffuse large B-cell lymphoma; Pegfilgrastim; Prophylaxis |
| المشرفين على المادة: | 143011-72-7 (Granulocyte Colony-Stimulating Factor) 3A58010674 (pegfilgrastim) 3WJQ0SDW1A (Polyethylene Glycols) 4F4X42SYQ6 (Rituximab) 5J49Q6B70F (Vincristine) 80168379AG (Doxorubicin) 8N3DW7272P (Cyclophosphamide) 9PHQ9Y1OLM (Prednisolone) PVI5M0M1GW (Filgrastim) VB0R961HZT (Prednisone) |
| تواريخ الأحداث: | Date Created: 20220106 Date Completed: 20221018 Latest Revision: 20221028 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC9582490 |
| DOI: | 10.4143/crt.2021.1168 |
| PMID: | 34990525 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2005-9256 |
|---|---|
| DOI: | 10.4143/crt.2021.1168 |